# A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC

> **NCT04950400** · NA · UNKNOWN · sponsor: **Beijing Chest Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Non-small Cell Lung Cancer

## Interventions

- **DRUG:** Carrelizumab + chemotherapy + apatinib

## Key facts

- **NCT ID:** NCT04950400
- **Lead sponsor:** Beijing Chest Hospital
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-07-07
- **Primary completion:** 2023-12-12
- **Final completion:** 2024-04-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2021-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04950400

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04950400, "A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib Treatment of Advanced NSCLC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04950400. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*